問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Chia-Yi Christian Hosptal

Recruiting

List

41Cases

2025-09-23 - 2028-02-13

Phase II

Active
A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects with Chronic Hepatitis B Virus Infection (B-SUPREME)

  • Condition/Disease

    Chronic hepatitis B virus (HBV) infection

  • Test Drug

    Film-coated tablet Film-coated tablet

Participate Sites
8Sites

Recruiting8Sites

2022-01-01 - 2025-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2024-11-15 - 2032-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-10-15 - 2029-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-06-01 - 2026-12-31

Phase II

Active
A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis

  • Condition/Disease

    Non-alcoholic Fatty Liver Disease

  • Test Drug

    MK-6024

Participate Sites
7Sites

Recruiting7Sites

2025-07-01 - 2035-12-31

Phase III

Not yet recruiting
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

  • Condition/Disease

    Breast Neoplasms

  • Test Drug

    注射劑 錠劑 注射劑 注射劑

Participate Sites
7Sites

Recruiting7Sites

2023-10-02 - 2026-12-31

Phase III

Completed
A Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of the Proposed Biosimilar PERT-IJS and EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Patients With Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Stage or Locally Advanced Breast Cancer

  • Condition/Disease

    HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

  • Test Drug

    PERT-IJS (Bmab 1500)

Participate Sites
7Sites

Recruiting7Sites

2023-05-01 - 2024-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

2025-01-01 - 2030-01-31

Phase III

Active
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non- alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis

  • Condition/Disease

    cirrhosis

  • Test Drug

    N/A

Participate Sites
11Sites

Recruiting11Sites

2025-01-01 - 2032-12-31

Phase III

Active
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with non- cirrhotic non-alcoholic steatohepatitis/metabolic dysfunction- associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis

  • Condition/Disease

    liver fibrosis

  • Test Drug

    N/A

Participate Sites
11Sites

Recruiting11Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB